TACSTD2 and neoplasm: YH012 was also shown to be more selective for HER2+/TROP2+ cells rather than single target-positive cells, thereby enhancing tumor specificity and potentially reducing on-target toxicity compared with monospecific HER2 or TROP2 ADCs.